Massimo Bigio

Title: Massimo Bigio: Innovator in Conjugate Purification

Introduction

Massimo Bigio is a notable inventor based in Siena, Italy. He has made significant contributions to the field of biotechnology, particularly in the purification of saccharide antigen-carrier protein conjugates. His work has implications for vaccine development, showcasing the intersection of innovation and public health.

Latest Patents

Massimo Bigio holds a patent related to conjugate purification. This patent, which is focused on methods for purifying saccharide antigen-carrier protein conjugates, provides a novel approach to separating these conjugates from free carrier proteins, such as CRM197. The invention utilizes hydroxyapatite for purification and further relates to methods of preparing vaccines using this innovative technique. He has 1 patent to his name.

Career Highlights

Throughout his career, Massimo Bigio has worked with prominent companies in the pharmaceutical industry. He has been associated with GlaxoSmithKline Biologicals and Novartis AG, where he has contributed to advancements in vaccine technology and biopharmaceuticals. His expertise in purification methods has been instrumental in enhancing the efficacy of vaccine formulations.

Collaborations

Massimo Bigio has collaborated with esteemed colleagues in his field, including Giovanni Averani and Francesco Norelli. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Massimo Bigio's contributions to the field of biotechnology, particularly in conjugate purification, highlight his role as an innovator. His work not only advances scientific knowledge but also has practical applications in vaccine development.